Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 293


Mutant p53-a potential player in shaping the tumor-stroma crosstalk.

Stein Y, Aloni-Grinstein R, Rotter V.

J Mol Cell Biol. 2019 Jul 19;11(7):600-604. doi: 10.1093/jmcb/mjz071.


Liver and Steroid Hormones-Can a Touch of p53 Make a Difference?

Charni-Natan M, Aloni-Grinstein R, Osher E, Rotter V.

Front Endocrinol (Lausanne). 2019 Jun 12;10:374. doi: 10.3389/fendo.2019.00374. eCollection 2019. Review.


Correction: Cancer therapeutic approach based on conformational stabilization of mutant p53 protein by small peptides.

Tal P, Eizenberger S, Cohen E, Goldfinger N, Pietrokovski S, Oren M, Rotter V.

Oncotarget. 2019 May 7;10(34):3203-3206. doi: 10.18632/oncotarget.26921. eCollection 2019 May 7.


Multi-element chemical analysis of printed circuit boards - challenges and pitfalls.

Korf N, Løvik AN, Figi R, Schreiner C, Kuntz C, Mählitz PM, Rösslein M, Wäger P, Rotter VS.

Waste Manag. 2019 Jun 1;92:124-136. doi: 10.1016/j.wasman.2019.04.061. Epub 2019 May 20.


Retraction: Transactivation of the EGR1 Gene Contributes to Mutant p53 Gain of Function.

Weisz L, Zalcenstein A, Stambolsky P, Cohen Y, Goldfinger N, Oren M, Rotter V.

Cancer Res. 2019 Apr 15;79(8):2085. doi: 10.1158/0008-5472.CAN-19-0560. No abstract available.


p53 balances between tissue hierarchy and anarchy.

Koifman G, Aloni-Grinstein R, Rotter V.

J Mol Cell Biol. 2019 Jul 19;11(7):553-563. doi: 10.1093/jmcb/mjz022.


The HIV gp41 Fusion Protein Inhibits T-Cell Activation through the Lentiviral Lytic Peptide 2 Motif.

Klug YA, Schwarzer R, Rotem E, Charni M, Nudelman A, Gramatica A, Zarmi B, Rotter V, Shai Y.

Biochemistry. 2019 Feb 12;58(6):818-832. doi: 10.1021/acs.biochem.8b01175. Epub 2019 Jan 15.


Mutant p53-dependent mitochondrial metabolic alterations in a mesenchymal stem cell-based model of progressive malignancy.

Lonetto G, Koifman G, Silberman A, Attery A, Solomon H, Levin-Zaidman S, Goldfinger N, Porat Z, Erez A, Rotter V.

Cell Death Differ. 2019 Sep;26(9):1566-1581. doi: 10.1038/s41418-018-0227-z. Epub 2018 Nov 9.


A Mutant p53-Dependent Embryonic Stem Cell Gene Signature Is Associated with Augmented Tumorigenesis of Stem Cells.

Koifman G, Shetzer Y, Eizenberger S, Solomon H, Rotkopf R, Molchadsky A, Lonetto G, Goldfinger N, Rotter V.

Cancer Res. 2018 Oct 15;78(20):5833-5847. doi: 10.1158/0008-5472.CAN-18-0805. Epub 2018 Aug 28.


p53 and the Viral Connection: Back into the Future .

Aloni-Grinstein R, Charni-Natan M, Solomon H, Rotter V.

Cancers (Basel). 2018 Jun 4;10(6). pii: E178. doi: 10.3390/cancers10060178. Review.


Various stress stimuli rewire the profile of liver secretome in a p53-dependent manner.

Charni-Natan M, Solomon H, Molchadsky A, Jacob-Berger A, Goldfinger N, Rotter V.

Cell Death Dis. 2018 May 29;9(6):647. doi: 10.1038/s41419-018-0697-4.


The HTLV-1 gp21 fusion peptide inhibits antigen specific T-cell activation in-vitro and in mice.

Rotem E, Faingold O, Charni M, Klug YA, Harari D, Shmuel-Galia L, Nudelman A, Rotter V, Shai Y.

PLoS Pathog. 2018 May 4;14(5):e1007044. doi: 10.1371/journal.ppat.1007044. eCollection 2018 May.


Mutant p53 gain of function underlies high expression levels of colorectal cancer stem cells markers.

Solomon H, Dinowitz N, Pateras IS, Cooks T, Shetzer Y, Molchadsky A, Charni M, Rabani S, Koifman G, Tarcic O, Porat Z, Kogan-Sakin I, Goldfinger N, Oren M, Harris CC, Gorgoulis VG, Rotter V.

Oncogene. 2018 Mar;37(12):1669-1684. doi: 10.1038/s41388-017-0060-8. Epub 2018 Jan 18.


Diverse p53/DNA binding modes expand the repertoire of p53 response elements.

Vyas P, Beno I, Xi Z, Stein Y, Golovenko D, Kessler N, Rotter V, Shakked Z, Haran TE.

Proc Natl Acad Sci U S A. 2017 Oct 3;114(40):10624-10629. doi: 10.1073/pnas.1618005114. Epub 2017 Sep 14.


Post-translational regulation of p53 function through 20S proteasome-mediated cleavage.

Solomon H, Bräuning B, Fainer I, Ben-Nissan G, Rabani S, Goldfinger N, Moscovitz O, Shakked Z, Rotter V, Sharon M.

Cell Death Differ. 2017 Dec;24(12):2187-2198. doi: 10.1038/cdd.2017.139. Epub 2017 Sep 8.


Dysfunctional diversity of p53 proteins in adult acute myeloid leukemia: projections on diagnostic workup and therapy.

Prokocimer M, Molchadsky A, Rotter V.

Blood. 2017 Aug 10;130(6):699-712. doi: 10.1182/blood-2017-02-763086. Epub 2017 Jun 12. Review.


High Throughput Analysis of Golgi Structure by Imaging Flow Cytometry.

Wortzel I, Koifman G, Rotter V, Seger R, Porat Z.

Sci Rep. 2017 Apr 11;7(1):788. doi: 10.1038/s41598-017-00909-y.


p53 and its mutants on the slippery road from stemness to carcinogenesis.

Molchadsky A, Rotter V.

Carcinogenesis. 2017 Apr 1;38(4):347-358. doi: 10.1093/carcin/bgw092. Review.


Linking energy-sanitation-agriculture: Intersectional resource management in smallholder households in Tanzania.

Krause A, Rotter VS.

Sci Total Environ. 2017 Jul 15;590-591:514-530. doi: 10.1016/j.scitotenv.2017.02.205. Epub 2017 Mar 7.


Challenges for critical raw material recovery from WEEE - The case study of gallium.

Ueberschaar M, Otto SJ, Rotter VS.

Waste Manag. 2017 Feb;60:534-545. doi: 10.1016/j.wasman.2016.12.035. Epub 2017 Jan 12.


Differential regulated microRNA by wild type and mutant p53 in induced pluripotent stem cells.

Grespi F, Landré V, Molchadsky A, Di Daniele N, Marsella LT, Melino G, Rotter V.

Cell Death Dis. 2016 Dec 29;7(12):e2567. doi: 10.1038/cddis.2016.419.


Immune deficiency augments the prevalence of p53 loss of heterozygosity in spontaneous tumors but not bi-directional loss of heterozygosity in bone marrow progenitors.

Shetzer Y, Napchan Y, Kaufman T, Molchadsky A, Tal P, Goldfinger N, Rotter V.

Int J Cancer. 2017 Mar 15;140(6):1364-1369. doi: 10.1002/ijc.30554.


p53 on the crossroad between regeneration and cancer.

Charni M, Aloni-Grinstein R, Molchadsky A, Rotter V.

Cell Death Differ. 2017 Jan;24(1):8-14. doi: 10.1038/cdd.2016.117. Epub 2016 Oct 21. Review.


TM7SF3, a novel p53-regulated homeostatic factor, attenuates cellular stress and the subsequent induction of the unfolded protein response.

Isaac R, Goldstein I, Furth N, Zilber N, Streim S, Boura-Halfon S, Elhanany E, Rotter V, Oren M, Zick Y.

Cell Death Differ. 2017 Jan;24(1):132-143. doi: 10.1038/cdd.2016.108. Epub 2016 Oct 14.


Cellular heterogeneity mediates inherent sensitivity-specificity tradeoff in cancer targeting by synthetic circuits.

Morel M, Shtrahman R, Rotter V, Nissim L, Bar-Ziv RH.

Proc Natl Acad Sci U S A. 2016 Jul 19;113(29):8133-8. doi: 10.1073/pnas.1604391113. Epub 2016 Jul 6.


Capturing tumor complexity in vitro: Comparative analysis of 2D and 3D tumor models for drug discovery.

Stock K, Estrada MF, Vidic S, Gjerde K, Rudisch A, Santo VE, Barbier M, Blom S, Arundkar SC, Selvam I, Osswald A, Stein Y, Gruenewald S, Brito C, van Weerden W, Rotter V, Boghaert E, Oren M, Sommergruber W, Chong Y, de Hoogt R, Graeser R.

Sci Rep. 2016 Jul 1;6:28951. doi: 10.1038/srep28951.


Targeting mutant p53 for cancer therapy.

Oren M, Tal P, Rotter V.

Aging (Albany NY). 2016 Jun;8(6):1159-60. doi: 10.18632/aging.100992. No abstract available.


Oncogenic Mutant p53 Gain of Function Nourishes the Vicious Cycle of Tumor Development and Cancer Stem-Cell Formation.

Shetzer Y, Molchadsky A, Rotter V.

Cold Spring Harb Perspect Med. 2016 Oct 3;6(10). pii: a026203. doi: 10.1101/cshperspect.a026203. Review.


Cancer therapeutic approach based on conformational stabilization of mutant p53 protein by small peptides.

Tal P, Eizenberger S, Cohen E, Goldfinger N, Pietrokovski S, Oren M, Rotter V.

Oncotarget. 2016 Mar 15;7(11):11817-37. doi: 10.18632/oncotarget.7857.


Novel p53 target genes secreted by the liver are involved in non-cell-autonomous regulation.

Charni M, Molchadsky A, Goldstein I, Solomon H, Tal P, Goldfinger N, Yang P, Porat Z, Lozano G, Rotter V.

Cell Death Differ. 2016 Mar;23(3):509-20. doi: 10.1038/cdd.2015.119. Epub 2015 Sep 11.


Battery related cobalt and REE flows in WEEE treatment.

Sommer P, Rotter VS, Ueberschaar M.

Waste Manag. 2015 Nov;45:298-305. doi: 10.1016/j.wasman.2015.05.009. Epub 2015 Jun 6.


p53 in liver pathologies-taking the good with the bad.

Charni M, Rivlin N, Molchadsky A, Aloni-Grinstein R, Rotter V.

J Mol Med (Berl). 2014 Dec;92(12):1229-34. doi: 10.1007/s00109-014-1223-5. Epub 2014 Nov 19. Review.


Modulation of alternative splicing contributes to cancer development: focusing on p53 isoforms, p53β and p53γ.

Solomon H, Sharon M, Rotter V.

Cell Death Differ. 2014 Sep;21(9):1347-9. doi: 10.1038/cdd.2014.99. No abstract available.


Endothelial matrix assembly during capillary morphogenesis: insights from chimeric TagRFP-fibronectin matrix.

Chang F, Lemmon CA, Nilaratanakul V, Rotter V, Romer L.

J Histochem Cytochem. 2014 Nov;62(11):774-90. doi: 10.1369/0022155414547419. Epub 2014 Jul 25.


Pla2g16 phospholipase mediates gain-of-function activities of mutant p53.

Xiong S, Tu H, Kollareddy M, Pant V, Li Q, Zhang Y, Jackson JG, Suh YA, Elizondo-Fraire AC, Yang P, Chau G, Tashakori M, Wasylishen AR, Ju Z, Solomon H, Rotter V, Liu B, El-Naggar AK, Donehower LA, Martinez LA, Lozano G.

Proc Natl Acad Sci U S A. 2014 Jul 29;111(30):11145-50. doi: 10.1073/pnas.1404139111. Epub 2014 Jul 14.


The onset of p53 loss of heterozygosity is differentially induced in various stem cell types and may involve the loss of either allele.

Shetzer Y, Kagan S, Koifman G, Sarig R, Kogan-Sakin I, Charni M, Kaufman T, Zapatka M, Molchadsky A, Rivlin N, Dinowitz N, Levin S, Landan G, Goldstein I, Goldfinger N, Pe'er D, Radlwimmer B, Lichter P, Rotter V, Aloni-Grinstein R.

Cell Death Differ. 2014 Sep;21(9):1419-31. doi: 10.1038/cdd.2014.57. Epub 2014 May 16.


Rescue of embryonic stem cells from cellular transformation by proteomic stabilization of mutant p53 and conversion into WT conformation.

Rivlin N, Katz S, Doody M, Sheffer M, Horesh S, Molchadsky A, Koifman G, Shetzer Y, Goldfinger N, Rotter V, Geiger T.

Proc Natl Acad Sci U S A. 2014 May 13;111(19):7006-11. doi: 10.1073/pnas.1320428111. Epub 2014 Apr 28.


The paradigm of mutant p53-expressing cancer stem cells and drug resistance.

Shetzer Y, Solomon H, Koifman G, Molchadsky A, Horesh S, Rotter V.

Carcinogenesis. 2014 Jun;35(6):1196-208. doi: 10.1093/carcin/bgu073. Epub 2014 Mar 21. Review.


The inflammatory cytokine TNFα cooperates with Ras in elevating metastasis and turns WT-Ras to a tumor-promoting entity in MCF-7 cells.

Leibovich-Rivkin T, Liubomirski Y, Meshel T, Abashidze A, Brisker D, Solomon H, Rotter V, Weil M, Ben-Baruch A.

BMC Cancer. 2014 Mar 6;14:158. doi: 10.1186/1471-2407-14-158.


p53: the barrier to cancer stem cell formation.

Aloni-Grinstein R, Shetzer Y, Kaufman T, Rotter V.

FEBS Lett. 2014 Aug 19;588(16):2580-9. doi: 10.1016/j.febslet.2014.02.011. Epub 2014 Feb 19.


p53 orchestrates between normal differentiation and cancer.

Rivlin N, Koifman G, Rotter V.

Semin Cancer Biol. 2015 Jun;32:10-7. doi: 10.1016/j.semcancer.2013.12.006. Epub 2014 Jan 7. Review.


p53 promotes the expression of gluconeogenesis-related genes and enhances hepatic glucose production.

Goldstein I, Yizhak K, Madar S, Goldfinger N, Ruppin E, Rotter V.

Cancer Metab. 2013 Feb 4;1(1):9. doi: 10.1186/2049-3002-1-9.


Data availability and the need for research to localize, quantify and recycle critical metals in information technology, telecommunication and consumer equipment.

Chancerel P, Rotter VS, Ueberschaar M, Marwede M, Nissen NF, Lang KD.

Waste Manag Res. 2013 Oct;31(10 Suppl):3-16. doi: 10.1177/0734242X13499814.


'Cancer associated fibroblasts'--more than meets the eye.

Madar S, Goldstein I, Rotter V.

Trends Mol Med. 2013 Aug;19(8):447-53. doi: 10.1016/j.molmed.2013.05.004. Epub 2013 Jun 13. Review.


Mutant p53 prolongs NF-κB activation and promotes chronic inflammation and inflammation-associated colorectal cancer.

Cooks T, Pateras IS, Tarcic O, Solomon H, Schetter AJ, Wilder S, Lozano G, Pikarsky E, Forshew T, Rosenfeld N, Harpaz N, Itzkowitz S, Harris CC, Rotter V, Gorgoulis VG, Oren M.

Cancer Cell. 2013 May 13;23(5):634-46. doi: 10.1016/j.ccr.2013.03.022. Erratum in: Cancer Cell. 2013 Aug 12;24(2):272. Rozenfeld, Nitzan [corrected to Rosenfeld, Nitzan].


p63 attenuates epithelial to mesenchymal potential in an experimental prostate cell model.

Olsen JR, Oyan AM, Rostad K, Hellem MR, Liu J, Li L, Micklem DR, Haugen H, Lorens JB, Rotter V, Ke XS, Lin B, Kalland KH.

PLoS One. 2013 May 1;8(5):e62547. doi: 10.1371/journal.pone.0062547. Print 2013.


Mutant p53 attenuates the anti-tumorigenic activity of fibroblasts-secreted interferon beta.

Madar S, Harel E, Goldstein I, Stein Y, Kogan-Sakin I, Kamer I, Solomon H, Dekel E, Tal P, Goldfinger N, Friedlander G, Rotter V.

PLoS One. 2013 Apr 22;8(4):e61353. doi: 10.1371/journal.pone.0061353. Print 2013.


p53 is required for brown adipogenic differentiation and has a protective role against diet-induced obesity.

Molchadsky A, Ezra O, Amendola PG, Krantz D, Kogan-Sakin I, Buganim Y, Rivlin N, Goldfinger N, Folgiero V, Falcioni R, Sarig R, Rotter V.

Cell Death Differ. 2013 May;20(5):774-83. doi: 10.1038/cdd.2013.9. Epub 2013 Feb 15.


Environmental evaluation of waste treatment scenarios for the towns Khanty-Mansiysk and Surgut, Russia.

Kaazke J, Meneses M, Wilke BM, Rotter VS.

Waste Manag Res. 2013 Mar;31(3):315-26. doi: 10.1177/0734242X12473792. Epub 2013 Feb 4.


Epigenetic polymorphism and the stochastic formation of differentially methylated regions in normal and cancerous tissues.

Landan G, Cohen NM, Mukamel Z, Bar A, Molchadsky A, Brosh R, Horn-Saban S, Zalcenstein DA, Goldfinger N, Zundelevich A, Gal-Yam EN, Rotter V, Tanay A.

Nat Genet. 2012 Nov;44(11):1207-14. doi: 10.1038/ng.2442. Epub 2012 Oct 14.


Supplemental Content

Loading ...
Support Center